<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2201233140
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        COLISTIN JPI Powder For Solution For Injection/Infusion
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        COLISTIMETHATE SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1000000
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        IU
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        357.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="HIKMA ITALIA SPA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            HIKMA ITALIA SPA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01XB01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Colistin JPI contains the active substance colistimethate sodium. Colistimethate sodium is an antibiotic. It belongs to a group of antibiotics that are called polymyxins.</p><p>&nbsp;</p><p>Colistin JPI is given by injection to treat some types of serious infections caused by certain bacteria. Colistin JPI is used when other antibiotics are not suitable.</p><p>&nbsp;</p><p>Colistin JPI is given as an inhalation to treat chronic chest infections in patients with cystic fibrosis. Colistin JPI is used when these infections are caused by specific bacteria called Pseudomonas aeruginosa.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Colistin JPI </strong></p><ul><li>If you are allergic to colistimethate sodium, colistin or to other polymyxins.</li></ul><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor, pharmacist or nurse before using Colistin JPI:</p><ul><li>If you have or have had kidney problems.</li><li>If you suffer from myasthenia gravis.</li><li>If you suffer from porphyria.</li><li>If you suffer from asthma.</li></ul><p>&nbsp;</p><p>If you experience muscle spasm, fatigue or Increased urine output at any time, tell your doctor immediately as these events<em> </em>maybe related to a condition known as pseudo-Bartter syndrome.</p><p>&nbsp;</p><p>Some people may experience a feeling of tightness in the chest due to narrowing of the airways when inhaling Colistin JPI. Your doctor may prescribe other medicines for inhalation directly before or after using Colistin JPI; in order to prevent or treat this.</p><p>&nbsp;</p><p><strong>Children</strong><br />In premature and new-born babies, special care should be taken when using Colistin JPI as the kidneys are not yet fully developed.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Colistin JPI</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>If you are taking any of the following medicines, you may or may not be able to take Colistin JPI.</p><p>&nbsp;</p><p>Sometimes the other medicines must be stopped (if only for a while) or you may need a lower dose of Colistin JPI or you may need to be monitored while you are taking Colistin JPI. In some cases, the level of Colistin JPI in your blood may have to be measured from time to time to make sure that you are having the right dose.</p><ul><li>Medicines like antibiotics called aminoglycosides (which include gentamicin, tobramycin, amikacin and netilmicin) and cephalosporins which can affect how your kidneys function. Taking such medicines at the same time as colistimethate sodium can increase the risk of damage to the kidneys (see section 4 of this leaflet).</li><li>Medicines like antibiotics called aminoglycosides (which include gentamicin, tobramycin, amikacin and netilmicin) which can affect your nervous system. Taking such medicines at the same time as colistimethate sodium can increase the risk of side effects in the ears and other parts of your nervous system (see section 4 of this leaflet).</li><li>Medicines called muscle relaxants, often used during general anaesthesia. Colistimethate sodium can increase the effects of these medicines. If you have a general anaesthetic, let your anaesthetist know that you are having colistimethate sodium.</li></ul><p>&nbsp;</p><p>If you suffer from myasthenia gravis and are also taking other antibiotics called macrolides (such as azithromycin, clarithromycin or erythromycin) or antibiotics called fluoroquinolones (such as ofloxacin, norfloxacin and ciprofloxacin), taking colistimethate sodium further increases the risk of muscle weakness and breathing difficulties.</p><p>&nbsp;</p><p>Having colistimethate sodium as an infusion at the same time as receiving colistimethate sodium as an inhalation can increase your risk of side effects.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>Colistimethate sodium is not known to harm the unborn child but, like all medicines, it will only be given to a pregnant woman if it is really needed.</p><p>&nbsp;</p><p>Are you breast-feeding? Small amounts of colistimethate sodium enter the milk. If you cannot stop breast-feeding while you take Colistin JPI, you should watch your baby carefully for any signs of illness and tell your doctor if you notice anything wrong.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>When colistimethate sodium is given into a vein there may be side effects such as dizziness, confusion or problems with vision. If these occur, you should not drive or operate machinery.</p><p>&nbsp;</p><p><strong>Colistin JPI contains sodium</strong></p><p>Colistin JPI contains sodium. Each vial of Colistin JPI 1,000,000 IU and 2,000,000 IU Powder for Solution for Injection/Infusion/Inhalation contains 0.2286 mmol (5.258 mg) or 0.458 mmol (10.534 mg) sodium (main component of cooking/table salt); respectively. This is equivalent to 0.2629% or 0.5267%; respectively of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Depending on the reason (see section 1 of this leaflet), Colistin JPI may be given by fast injection (over 5 minutes into a special kind of tube in a vein) or slow injection (infusion over about 30 to 60 minutes) into a vein.</p><p>&nbsp;</p><p>Colistin JPI may occasionally be given by injection into the brain or the spine.</p><p>&nbsp;</p><p>Colistin JPI can also be breathed into the lungs as a fine spray made using a machine called a nebuliser. The droplets of the spray produced by the nebuliser are small enough to enter the lungs so that Colistin JPI can reach the site of the bacterial infection.</p><p>&nbsp;</p><p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong><em>For use by infusion or injection:</em></strong></p><p>Colistin JPI is given to you by your doctor as an infusion into a vein over 30 &ndash; 60 minutes.</p><p>&nbsp;</p><p>The usual daily dose in adults is 9 million units, divided into two or three doses. If you are quite unwell, you will be given a higher dose of 9 million units once at the start of treatment.</p><p>&nbsp;</p><p>In some cases, your doctor may decide to give a higher daily dose of up to 12 million units.</p><p>&nbsp;</p><p>The usual daily dose in children weighing up to 40 kg is 75,000 to 150,000 units per kilogram body weight, divided into three doses.</p><p>&nbsp;</p><p>Higher doses have occasionally been given in cystic fibrosis.</p><p>&nbsp;</p><p>Children and adults with kidney problems, including those on dialysis, are usually given lower doses. Your doctor will monitor your kidney function regularly while you receive Colistin JPI.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p>Colistin JPI is given by injection mainly in hospitals. If you are to treat yourself at home, your doctor, pharmacist or nurse will show you how to dissolve the powder and inject the right dose of solution.</p><p>&nbsp;</p><p><em>Duration of treatment</em></p><p>Your doctor will decide how long your treatment should last depending on the severity of the infection. When treating bacterial infections it is important to complete the full course of treatment so as to prevent worsening of the existing infection.</p><p>&nbsp;</p><p><strong><em>For use in a nebuliser:</em></strong></p><p>The usual dose for adults, adolescents and children aged 2 years or older is 1-2 million units two to three times per day (maximum 6 million units per day).</p><p>&nbsp;</p><p>The usual dose for children less than 2 years old is 0.5-1 million units twice daily (maximum 2 million units per day).</p><p>&nbsp;</p><p>Your doctor may decide to adjust the dose depending on your circumstances. If you also take other inhaled medicines, your doctor will tell you which order to take them in.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p>If you are treating yourself at home, your doctor, pharmacist or nurse will show you how to use Colistin JPI in your nebuliser when you first start the treatment. You should sit upright and breathe normally during inhalation. The following are general instructions.</p><p><em>&nbsp;</em></p><p><em>Preparation for inhalation treatment</em></p><p>Before Colistin JPI can be used it must be dissolved in isotonic saline solution (salt water).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>To start your treatment, you will need the following:</p><ul><li>One clear-glass vial of Colistin JPI 1,000,000 IU</li><li>The solvent for dissolving the powder (3 ml of isotonic saline solution)</li><li>A nebuliser appropriate for inhalation use of Colistin JPI 1,000,000 IU</li></ul></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>To start your treatment, you will need the following:</p><ul><li>One clear-glass vial of Colistin JPI 2,000,000 IU</li><li>The solvent for dissolving the powder (4 ml of isotonic saline solution)</li><li>A nebuliser appropriate for inhalation use of Colistin JPI 2,000,000 IU</li></ul></td></tr></tbody></table><p>&nbsp;</p><p>It is important that your nebuliser system functions properly before starting your treatment with Colistin JPI. Read carefully the instructions for use of the nebuliser for further information on handling the nebuliser system.</p><p>&nbsp;</p><p>Place the components of your nebuliser on a clean flat surface and follow the manufacturer&#39;s instructions for use.</p><p>&nbsp;</p><p><em>Preparing your Colistin JPI for inhalation</em></p><p>Colistin JPI must be used immediately after dissolution. Do not dissolve Colistin JPI until ready to administer a dose (see also section 5).</p><p>&nbsp;</p><p>Step 1: Take one vial of Colistin JPI and gently tap the glass vial so that the powder settles to the bottom. This helps ensure you get the proper dose<em> </em>of medication. Open the drug vial by lifting up the flip-off cap on the top.</p><p>&nbsp;</p><p>Step 2: Pull down to carefully remove the entire flip-off cap from the vial. Safely dispose of the ring and flip-off cap.</p><p>&nbsp;</p><p>Step 3: Carefully remove the rubber stopper.</p><p>&nbsp;</p><p>Colistin JPI 1,000,000 IU: Add the solvent (3 ml of isotonic saline solution) to the corresponding vial to dissolve the powder:</p><p>Colistin JPI 2,000,000 IU: Add the solvent (4 ml of isotonic saline solution) to the corresponding vial to dissolve the powder:</p><p>In order to avoid foaming, shake the vial gently until all powder is dissolved. Pour the solution into the nebuliser.</p><p>Do not use Colistin JPI if you notice visible particles in the solution after dissolution.</p><p>&nbsp;</p><p>Once prepared Colistin JPI should be used immediately. Any unused solution should be disposed of.</p><p><em>&nbsp;</em></p><p><em>Using your Colistin JPI</em></p><p>Colistin JPI is for inhalation use with an appropriate nebuliser.</p><p>&nbsp;</p><p>For more detailed information on correct use of the selected<em> </em>nebuliser follow the instruction manual of the nebuliser.</p><p>&nbsp;</p><p>Inhalation should take place in a well ventilated room.</p><p>&nbsp;</p><p><em>After inhalation of Colistin JPI</em></p><p>Please refer to the manufacturer&#39;s instructions for use of the nebuliser for cleaning and disinfecting instructions.</p><p>&nbsp;</p><p>IMPORTANT: Do not mix Colistin JPI with any other product for nebulisation at the same time.</p><p>&nbsp;</p><p><em>Duration of treatment</em></p><p>For nebulised use your doctor will advise on the course of the treatment.</p><p>&nbsp;</p><p><strong>If you use more Colistin JPI than you should </strong></p><p>If you think that you have given yourself too much Colistin JPI, you should contact your doctor or nurse immediately for advice or, if they are not available, contact or go to your nearest hospital accident and emergency department. If too much Colistin JPI is accidentally given, the side effects can be serious and can include kidney problems, muscle weakness and difficulty (or even stopping) breathing.</p><p>&nbsp;</p><p>If you are being treated in hospital or at home by a doctor or nurse and think that you may have missed a dose or been given too much Colistin JPI, please ask your doctor, nurse or pharmacist about this.</p><p>&nbsp;</p><p><strong>If you forget to use Colistin JPI</strong></p><p>If you are treating yourself and have missed any doses, you should give the missed dose as soon as you remember and then give the next dose 8 hours later if using Colistin JPI three times a day, or 12 hours later if using Colistin JPI twice a day. Carry on from there as instructed. Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>If you stop using Colistin JPI</strong></p><p>Do not stop your treatment early unless your doctor says you can. Your doctor will decide how long your treatment should last. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>&nbsp;</strong></p><p><strong>Allergic reactions</strong></p><p>Whether colistimethate sodium is given into a vein or by inhalation, an allergic reaction is possible. Serious allergic reactions can happen even with the very first dose and can include rapid development of rashes, swelling of the face, tongue and neck, inability to breathe due to narrowing of the airways and loss of consciousness.</p><p>&nbsp;</p><p>If you experience signs of an allergic reaction you should seek urgent medical attention.</p><p>&nbsp;</p><p>Less severe allergic reactions include skin rashes that appear later during treatment.</p><p>&nbsp;</p><p><strong>Side effects associated with injecting colistimethate sodium into a vein</strong></p><p>Side effects that affect the nervous system are more likely to occur when the dose of colistimethate sodium is too high, in people who have poor kidneys or in those who are also taking muscle relaxants or other medicines with a similar effect on how the nerves work.</p><p>&nbsp;</p><p>The most serious of these possible side effects in the nervous system is inability to breathe because of paralysis of the chest muscles. If you experience any difficulty breathing you should seek urgent medical attention.</p><p>&nbsp;</p><p>Other possible side effects include numbness or tingling (especially around the face), dizziness or loss of balance, rapid changes in blood pressure or blood flow (including faintness and flushing), slurred speech, problems with vision, confusion and mental problems (including loss of sense of reality).</p><p>&nbsp;</p><p>There can be reactions at the site of the injection, such as irritation.</p><p>&nbsp;</p><p>Kidney problems may also occur. These are especially likely in people who already have poor kidneys, or who are given colistimethate sodium at the same time as other medicines that can cause side effects in the kidneys or who are given a dose that is too high. These problems will normally get better if treatment is stopped or the dose of colistimethate sodium is reduced.</p><p>&nbsp;</p><p>You may experience, after intravenous administration, the following symptoms that may be related to a condition known as pseudo-Bartter syndrome (see section 2):</p><ul><li>Muscle spasm</li><li>Increase in urine output</li><li>Fatigue</li></ul><p>&nbsp;</p><p><strong>Side effects associated with inhaling colistimethate sodium (nebulisation)</strong></p><p>The risk of side effects is usually much less when it is given by inhalation because very little colistimethate sodium usually reaches the bloodstream when it is given this way.</p><p>&nbsp;</p><p>Possible side effects include coughing, a feeling of tightness in the chest due to narrowing of the airways, sore mouth or throat and thrush (Candida) infections of the mouth or throat.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 30&deg;C.</p><p>Store in the original package in order to protect from light.</p><p>Colistin JPI solutions for injection/infusion/inhalation should be used immediately after preparation.</p><p>If this is not possible, talk first to your doctor or pharmacist as the solutions may be stored for 2 hours at room temperature or for 6 hours in a refrigerator (2-8ᵒC) for 1,000,000 IU and for up to 24 hours at 2-8&deg;C for 2,000,000 IU. Any remaining solution should be discarded.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is colistimethate sodium.</p><p>&nbsp;</p><p>Each vial of Colistin JPI 1,000,000 IU Powder for Solution for Injection/Infusion/Inhalation contains 1,000,000 IU colistimethate sodium.</p><p>&nbsp;</p><p>Each vial of Colistin JPI 2,000,000 IU Powder for Solution for Injection/Infusion/Inhalation contains 2,000,000 IU colistimethate sodium.</p><p>&nbsp;</p><p>There are no other ingredients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Colistin JPI 1,000,000 IU Powder for Solution for Injection/Infusion/Inhalation is a white solid having characteristics appearance of products prepared by freeze drying in 10 ml type I clear glass vials with grey chlorobutyl rubber stoppers and transparent flip-off caps.

Colistin JPI 2,000,000 IU Powder for Solution for Injection/Infusion/Inhalation is a white solid having characteristics appearance of products prepared by freeze drying in 10 ml type I clear glass vials with grey chlorobutyl rubber stoppers and green flip-off caps.

Pack size: 10 Vials.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Batch releaser</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com</p><p>&nbsp;</p><p><strong>Bulk manufacturer</strong></p><p>Hikma Italia S.P.A.</p><p>Viale Certosa, 10</p><p>27100 Pavia, Italy</p><p>Tel: + (39-0382) 1751844/+ (39-0382) 1751801</p><p>Fax: + (39-0382) 422745</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p><ul><li>United Arab of Emirates</li></ul><p>Pharmacovigilance &amp; Medical Device Section</p><p>P.O. Box: 1853</p><p>Tel: 80011111</p><p>Email: pv@mohap.gov.ae</p><p>Drug Department</p><p>Ministry of Health &amp; Prevention</p><p>Dubai</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 07/2023; version number Un3.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي كوليستين JPI على المادة الفعالة كوليستيميثات الصوديوم. كوليستيميثات الصوديوم عبارة عن مضاد حيوي. وينتمي إلى مجموعة من المضادات الحيوية تسمى البوليميكسينات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء كوليستين JPI عن طريق الحقن لعلاج بعض حالات العدوى الخطيرة التي تسببها بكتيريا معينة. يستخدم كوليستين JPI عندما تكون المضادات الحيوية الأخرى غير مناسبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء كوليستين JPI عن طريق الاستنشاق لعلاج حالات عدوى الصدر المزمنة لدى المرضى المصابين بالتليف الكيسي. يستخدم كوليستين JPI عندما تحدث حالات العدوى هذه بسبب بكتيريا معينة تُسمى الزائفة الزنجارية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم كوليستين </strong><strong>JPI</strong><strong> </strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية لكوليستيميثات الصوديوم، كوليستين أو أي من البوليميكسينات الأخرى.</li></ul><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">تحدث مع طبيبك، الصيدلي أو الممرض قبل استخدام كوليستين JPI:</p><ul dir="rtl"><li>إذا كنت تعاني أو عانيت سابقاً من مشاكل في الكلى.</li><li>إذا كنت تعاني من الوهن العضلي الوبيل.</li><li>إذا كنت تعاني من البرفيرية.</li><li>إذا كنت تعاني من الربو.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من تشنج عضلي، إرهاق أو زيادة في كمية البول في أي وقت، أخبر طبيبك فوراً لأن هذه الأحداث قد تكون مرتبطة بحالة تعرف باسم متلازمة بارتر الزائفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يعاني بعض الأشخاص من شعور بضيق في الصدر بسبب ضيق المسالك الهوائية عند استنشاق كوليستين JPI. قد يصف طبيبك أدوية أخرى للاستنشاق مباشرةً قبل أو بعد استخدام كوليستين JPI بهدف منع ذلك الضيق أو علاجه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">يجب إعطاء عناية خاصة عند استخدام كوليستين JPI لدى الأطفال الخُدّج وحديثي الولادة نظراً إلى أن نمو الكلى لم يكتمل تماماً بعد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وكوليستين </strong><strong>JPI</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أخذت مؤخراً، أو قد تأخذ أية أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تأخذ أياً من الأدوية التالية، فقد تكون قادراً أو غير قادر على أخذ كوليستين JPI.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحياناً، يجب إيقاف الأدوية الأخرى (ولو لفترة من الوقت) أو قد تحتاج إلى جرعة أقل من كوليستين JPI أو قد تحتاج إلى الخضوع للمراقبة أثناء أخذ كوليستين JPI. في بعض الحالات، قد يلزم قياس مستوى كوليستين JPI في الدم من وقت لآخر للتأكد من أنك تأخذ الجرعة الصحيحة.</p><ul dir="rtl"><li>أدوية مثل مضادات حيوية تسمى أمينوجليكوزيدات (والتي تشمل جنتاميسين، توبراميسين، أميكاسين ونيتيلميسين) والسيفالوسبورينات التي يمكن أن تؤثر على مدى كفاءة كليتيك. قد يزيد أخذ هذه الأدوية مع كوليستيميثات الصوديوم في الوقت ذاته من خطر تلف الكلى (انظر القسم ٤ من هذه النشرة).</li><li>أدوية مثل مضادات حيوية تسمى أمينوجليكوزيدات (والتي تشمل جنتاميسين، توبراميسين، أميكاسين ونيتيلميسين) التي يمكن أن تؤثر على الجهاز العصبي. قد يزيد أخذ هذه الأدوية مع كوليستيميثات الصوديوم في الوقت ذاته من خطر الآثار الجانبية على الأذنين وأجزاء أخرى من الجهاز العصبي (انظر القسم ٤ من هذه النشرة).</li><li>الأدوية التي تسمى مرخيات العضلات، التي تستخدم غالباً أثناء التخدير العام. قد يزيد كوليستيميثات الصوديوم من آثار هذه الأدوية. أخبر طبيب التخدير أنك تأخذ كوليستيميثات الصوديوم إذا كنت ستخضع لتخدير عام.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من الوهن العضلي الوبيل وتأخذ أيضاً مضادات حيوية أخرى تسمى الماكروليدات (مثل أزيثروميسين، كلاريثروميسين أو إيريثروميسين) أو مضادات حيوية تسمى الفلوروكينولونات (مثل أوفلوكساسين، نورفلوكساسين وسيبروفلوكساسين)، فإن أخذ كوليستيميثات الصوديوم بالإضافة إلى ذلك يزيد من خطر الوهن العضلي وصعوبات التنفس.</p><p dir="RTL">قد يزيد أخذ كوليستيميثات الصوديوم عن طريق التسريب وأخذ كوليستيميثات الصوديوم عن طريق الاستنشاق في الوقت ذاته من خطر الآثار الجانبية لديك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">استشيري طبيبك أو الصيدلي إذا كنت حاملاً أو مرضع، تعتقدين بأنك حامل أو تخططين لذلك قبل أخذ هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم يثبت أن كوليستيميثات الصوديوم يسبب ضرراً للجنين، لكن، مثل جميع الأدوية، لا يتم إعطاؤه للمرأة الحامل إلا إذا احتاجت إليه فعلاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هل ترضعين رضاعة طبيعية؟ تدخل كميات صغيرة من كوليستيميثات الصوديوم إلى الحليب. إذا لم يكن بإمكانكِ إيقاف الرضاعة الطبيعية أثناء أخذ كوليستين JPI، فلا بد من مراقبة رضيعك بعناية بحثاً عن أي علامات للمرض وأخبري طبيبكِ إذا لاحظتِ أي شيء خاطئ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">عند إعطاء كوليستيميثات الصوديوم في الوريد قد تحدث آثار جانبية مثل الدوخة، الارتباك أو مشاكل في الرؤية. إذا حدثت هذه الآثار، فيجب عليك عدم القيادة أو تشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي كوليستين </strong><strong>JPI</strong><strong> على الصوديوم</strong></p><p dir="RTL">يحتوي كوليستين JPI على الصوديوم. تحتوي كل زجاجة من كوليستين JPI ١٠٠٠٠٠٠ وحدة دولية و٢٠٠٠٠٠٠ وحدة دولية مسحوق للحل للحقن/للتسريب/للاستنشاق على ٠،٢٢٨٦ ملمول (٥،٢٥٨ ملغم) أو ٠،٤٥٨ ملمول (١٠،٥٣٤ ملغم) صوديوم (المكون الرئيسي لملح الطعام/المائدة)؛ على التوالي. هذا يكافئ ٠،٢٦٢٩٪ أو ٠،٥٢٦٧%؛ على التوالي من الكمية الغذائية اليومية القصوى الموصى بها من الصوديوم للبالغ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اعتماداً على سبب الاستخدام (انظر القسم ١ من هذه النشرة)، يمكن إعطاء كوليستين JPI عن طريق الحقن السريع (خلال ٥ دقائق باستخدام نوع أنبوب خاص في الوريد) أو الحقن البطيء (التسريب خلال فترة تتراوح ما بين ٣٠ إلى ٦٠ دقيقة) في الوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إعطاء كوليستين JPI أحياناً عن طريق الحقن في الدماغ أو العمود الفقري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أيضاً استنشاق كوليستين JPI إلى داخل الرئتين باعتباره رذاذاً دقيقاً باستخدام جهاز يسمى الرذّاذ. تعتبر قطرات الرذاذ التي ينتجها الرذّاذ صغيرة بما يكفي لتدخل الرئتين بحيث يمكن وصول كوليستين JPI إلى موضع العدوى البكتيرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استخدم هذا الدواء دائماً كما وصفه لك طبيبك أو الصيدلي تماماً. تأكد من طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>للاستخدام عن طريق التسريب أو الحقن:</em></strong></p><p dir="RTL">يعطيك الطبيب كوليستين JPI عن طريق التسريب في الوريد خلال فترة تتراوح ما بين ٣٠ إلى ٦٠ دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة اليومية المعتادة للبالغين هي ٩ ملايين وحدة، مقسمة على جرعتين أو ثلاث جرعات. إذا شعرت بالتوعك الشديد، سيتم إعطاؤك جرعة أعلى تبلغ ٩ ملايين وحدة مرة واحدة في بداية العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في بعض الحالات، قد يقرر طبيبك إعطاء جرعة يومية أعلى تصل إلى ١٢ مليون وحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة اليومية المعتادة للأطفال الذين تصل أوزانهم إلى ٤٠ كغم هي ٧٥٠٠٠ إلى ١٥٠٠٠٠ وحدة لكل كيلوغرام من وزن الجسم، مقسمة على ثلاث جرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء جرعات أعلى أحياناً في حالات التليف الكيسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم عادةً إعطاء الأطفال والبالغين الذين يعانون من مشاكل في الكلى، ويشمل ذلك أولئك الذين يخضعون لغسيل الكلى، جرعات أقل. سيراقب الطبيب وظيفة الكلى لديك بانتظام أثناء تلقيك لكوليستين JPI.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>طريقة الاستخدام</em></p><p dir="RTL">يتم إعطاء كوليستين JPI عن طريق الحقن بشكل أساسي في المستشفيات. إذا كنت تعالج نفسك في المنزل، سيوضح لك طبيبك، الصيدلي أو الممرض طريقة إذابة المسحوق وحقن الجرعة الصحيحة من المحلول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>مدة العلاج</em></p><p dir="RTL">سيحدد طبيبك مدة العلاج التي يجب أن تستمر فيها اعتماداً على شدة العدوى. عند معالجة العدوى البكتيرية من المهم إنهاء دورة العلاج كاملة لمنع تفاقم العدوى الموجودة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>للاستخدام عن طريق الرذّاذ:</em></strong></p><p dir="RTL">الجرعة المعتادة للبالغين، المراهقين والأطفال الذين تبلغ أعمارهم عامين فأكثر هي ١-٢ مليون وحدة مرتين إلى ثلاث مرات في اليوم (الحد الأعلى ٦ ملايين وحدة في اليوم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة للأطفال الذين تقل أعمارهم عن عامين هي ٠،٥-١ مليون وحدة مرتين يومياً (الحد الأعلى ٢ مليون وحدة في اليوم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقرر طبيبك تعديل الجرعة حسب ظروفك. إذا كنت تأخذ أيضاً أدوية استنشاق أخرى، سيخبرك طبيبك بالترتيب الذي يمكنك اتباعه في أخذها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>طريقة الاستخدام</em></p><p dir="RTL">إذا كنت تعالج نفسك في المنزل، سيوضح لك طبيبك، الصيدلي أو الممرض طريقة استخدام كوليستين JPI عن طريق الرذّاذ عندما تبدأ العلاج للمرة الأولى. يجب عليك الجلوس في وضع مستقيم والتنفس بشكل طبيعي أثناء الاستنشاق. فيما يلي تعليمات عامة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>التجهيز للعلاج بالاستنشاق</em></p><p dir="RTL">قبل استخدام كوليستين JPI يجب إذابته في محلول ملحي متساوي الأسموزية (ماء ملحي).</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">لبدء علاجك، ستحتاج التالي:</p><ul dir="rtl"><li>زجاجة شفافة واحدة من كوليستين JPI ١٠٠٠٠٠٠ وحدة دولية</li><li>المحلول المذيب لإذابة المسحوق (٣ مللتر من محلول ملحي متساوي الأسموزية)</li><li>رذّاذ مناسب لاستخدام كوليستين JPI ١٠٠٠٠٠٠ وحدة دولية عن طريق الاستنشاق</li></ul></td></tr></tbody></table><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">لبدء علاجك، ستحتاج التالي:</p><ul dir="rtl"><li>زجاجة شفافة واحدة من كوليستين JPI ٢٠٠٠٠٠٠ وحدة دولية</li><li>المحلول المذيب لإذابة المسحوق (٤ مللتر من محلول ملحي متساوي الأسموزية)</li><li>رذّاذ مناسب لاستخدام كوليستين JPI ٢٠٠٠٠٠٠ وحدة دولية عن طريق الاستنشاق</li></ul></td></tr></tbody></table><p dir="RTL">من المهم أن يعمل نظام جهازك الرذّاذ بشكل صحيح قبل البدء بعلاجك باستخدام كوليستين JPI. اقرأ تعليمات استخدام الرذّاذ بعناية لمزيد من المعلومات عن التعامل مع نظام الرذّاذ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بوضع المحتويات في جهازك الرذّاذ على سطح مستوٍ نظيف واتبع تعليمات المصنع للاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>تجهيز </em><em>كوليستين </em><em>JPI</em><em> للاستنشاق</em></p><p dir="RTL">يجب استخدام<em> </em>كوليستين JPI مباشرة بعد الذوبان. لا تذب كوليستين JPI إلا بعد التجهّز لإعطاء جرعة (انظر أيضاً القسم ٥).</p><p dir="RTL">&nbsp;</p><p dir="RTL">الخطوة ١: قم بأخذ زجاجة واحدة من كوليستين JPI وانقر بلطف على الزجاجة ليستقر المسحوق في الأسفل. يساعد هذا على تلقيك الجرعة الصحيحة من الدواء. قم بفتح زجاجة الدواء من خلال رفع الغطاء القابل للفتح لأعلى الموجود في الأعلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الخطوة ٢: اسحب للأسفل بعناية لإزالة الغطاء القابل للفتح لأعلى بالكامل من الزجاجة. تخلص بشكل آمن من الحلقة والغطاء القابل للفتح لأعلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الخطوة ٣: قم بإزالة السدادة المطاطية بعناية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كوليستين JPI ١٠٠٠٠٠٠ وحدة دولية: أضف المذيب (٣ مللتر من المحلول الملحي متساوي الأسموزية) للزجاجة المناسبة لإذابة المسحوق:</p><p dir="RTL">كوليستين JPI ٢٠٠٠٠٠٠ وحدة دولية: أضف المذيب (٤ مللتر من المحلول الملحي متساوي الأسموزية) للزجاجة المناسبة لإذابة المسحوق:</p><p dir="RTL">لتجنب الرغوة، قم بخض الزجاجة برفق حتى يذوب المسحوق بالكامل. اسكب المحلول في الرذّاذ. لا تستخدم كوليستين JPI إذا لاحظت جزيئات واضحة في المحلول بعد الإذابة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بمجرد تحضير كوليستين JPI يجب استخدامه على الفور. يجب التخلص من أي محلول متبقي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>استخدام كوليستين </em><em>JPI</em><em> </em></p><p dir="RTL">يستخدم كوليستين JPI عن طريق الاستنشاق مع رذّاذ مناسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لمزيد من المعلومات حول الاستخدام الصحيح للرذّاذ الذي تم اختياره، اتبع تعليمات الدليل الخاص بالرذّاذ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب القيام بالاستنشاق في غرفة جيدة التهوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>بعد استنشاق كوليستين </em><em>JPI</em></p><p dir="RTL">يرجى اتباع تعليمات المصنع لاستخدام الرذّاذ لخطوات التنظيف والتعقيم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هام: لا تخلط كوليستين JPI مع أي مستحضر آخر للترذيذ في الوقت نفسه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>مدة العلاج</em></p><p dir="RTL">بالنسبة لاستخدام الرذّاذ، سوف ينصحك طبيبك بشأن فترة العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا استخدمت كوليستين </strong><strong>JPI</strong><strong> أكثر من اللازم</strong></p><p dir="RTL">إذا كنت تعتقد بأنك أعطيت نفسك جرعة كبيرة من كوليستين JPI، يجب عليك التواصل مع طبيبك أو الممرض على الفور لطلب النصيحة أو، إذا كانوا غير متاحين، اتصل أو اذهب إلى قسم الحوادث والطوارئ لأقرب مستشفى. إذا تم إعطاء جرعة من كوليستين JPI أكبر من اللازم عن طريق الخطأ، قد تكون الآثار الجانبية خطيرة ويمكن أن تشمل مشاكل في الكلى، الوهن العضلي وصعوبة (أو حتى توقف) التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تخضع للعلاج في المستشفى أو في البيت من قبل طبيب أو ممرض وتعتقد أنك قد فاتتك جرعة من كوليستين JPI أو تم إعطاؤك إياها أكثر من اللازم، يرجى سؤال طبيبك، الممرض أو الصيدلي عن ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام كوليستين </strong><strong>JPI</strong></p><p dir="RTL">إذا كنت تعالج نفسك وفاتتك أي جرعات، يجب أخذ الجرعة الفائتة بمجرد أن تتذكرها ومن ثم أخذ الجرعة التالية بعد مرور ٨ ساعات إذا كنت تستخدم كوليستين JPI ثلاث مرات في اليوم، أو بعد مرور ١٢&nbsp;ساعة إذا كنت تستخدم كوليستين JPI مرتين في اليوم. استمر من بعد ذلك حسب التعليمات. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام كوليستين </strong><strong>JPI</strong></p><p dir="RTL">لا توقف علاجك في وقت مبكر إلا إذا سمح طبيبك بذلك. سيحدد طبيبك مدة العلاج التي يجب أن تستمر عليها. إذا كان لديك أية أسئلة إضافية حول استخدام هذا الدواء، اسأل طبيبك، الصيدلي أو الممرض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>ردود الفعل التحسسية</strong></p><p dir="RTL">سواء تم إعطاء كوليستيميثات الصوديوم عن طريق الوريد أو الاستنشاق، فهناك احتمالية وجود رد فعل تحسسي. يمكن أن تحدث ردود فعل تحسسية خطيرة حتى مع الجرعة الأولى ويمكن أن تشمل ظهوراً سريعاً للطفح، تورم الوجه، اللسان والرقبة، عدم القدرة على التنفس بسبب ضيق المسالك الهوائية وفقدان الوعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من علامات رد فعل تحسسي يجب أن تطلب رعاية طبية عاجلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل ردود الفعل التحسسية الأقل حدة الطفح الجلدي الذي يظهر في وقت لاحق من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية المصاحبة لحقن كوليستيميثات الصوديوم في الوريد</strong></p><p dir="RTL">يزداد احتمالية حدوث الآثار الجانبية التي تؤثر على الجهاز العصبي عندما تكون جرعة كوليستيميثات الصوديوم عالية جداً، لدى المرضى الذين يعانون من ضعف في الكلى أو الذين يأخذون أيضاً أدوية مُرخية للعضلات أو أدوية أخرى لها تأثير مماثل على كيفية عمل الأعصاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتمثل أخطر تلك الآثار الجانبية المحتملة في الجهاز العصبي في عدم القدرة على التنفس بسبب شلل عضلات الصدر. إذا كنت تعاني من أي صعوبة في التنفس يجب أن تطلب رعاية طبية عاجلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل الآثار الجانبية المحتملة الأخرى التنميل أو الوخز (وخاصة حول الوجه)، الدوخة أو فقدان التوازن، التغيرات السريعة في ضغط الدم أو تدفق الدم (يشمل ذلك الإغماء واحمرار الوجه)، الكلام المتداخل، مشاكل في الرؤية، الارتباك والمشاكل النفسية (يشمل ذلك فقدان الشعور بالواقع).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يوجد ردود فعل في موضع الحقن، مثل التهيج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تحدث أيضاً مشاكل في الكلى. تزداد احتمالية ظهور هذه الأعراض لدى الأشخاص الذين يعانون بالأصل من ضعف في الكلى، أو الذين تم إعطاؤهم كوليستيميثات الصوديوم في الوقت نفسه مع أدوية أخرى يمكن أن تسبب آثاراً جانبية على الكلى أو الذين يتم إعطاؤهم جرعة عالية جداً. وستتحسن هذه المشاكل بشكل طبيعي إذا تم إيقاف العلاج أو إذا تم تقليل جرعة كوليستيميثات الصوديوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تواجه، بعد الإعطاء في الوريد، الأعراض التالية التي قد تكون مرتبطة بحالة تعرف باسم متلازمة بارتر الزائفة (انظر القسم ٢):</p><ul dir="rtl"><li>تشنّج عضلي</li><li>زيادة إخراج البول</li><li>تعب</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية المصاحبة لاستنشاق كوليستيميثات الصوديوم (الإرذاذ)</strong></p><p dir="RTL">يقل خطر الآثار الجانبية بشكل كبير عادةً عندما يتم إعطاؤه عن طريق الاستنشاق نظراً إلى وصول كمية قليلة من كوليستيميثات الصوديوم إلى مجرى الدم عادةً عند إعطائه بهذه الطريقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل الآثار الجانبية المحتملة السعال، الشعور بالضيق في الصدر بسبب ضيق المسالك الهوائية، التهاب الفم أو الحلق وعدوى القلاع (المُبيضَات) في الفم أو الحلق.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من ٣٠&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">يجب أن تُستخدم محاليل كوليستين JPI للحقن/للتسريب/للاستنشاق بعد تحضيرها على الفور.</p><p dir="RTL">إذا لم يكن ذلك ممكناً، تحدث أولاً إلى طبيبك أو الصيدلي حيث من الممكن تخزين المحاليل لمدة ساعتين عند درجة حرارة الغرفة أو لمدة ٦ ساعات في الثلاجة (٢-٨&deg; مئوية) لتركيز ١٠٠٠٠٠٠ وحدة دولية ولمدة تصل إلى ٢٤ ساعة عند درجة حرارة ٢-٨&deg; مئوية لتركيز ٢٠٠٠٠٠٠ وحدة دولية. يجب التخلص من أي محلول متبقي.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي كوليستيميثات الصوديوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل زجاجة من كوليستين JPI ١٠٠٠٠٠٠&nbsp;وحدة دولية مسحوق للحل للحقن/للتسريب/للاستنشاق على ١٠٠٠٠٠٠ وحدة دولية كوليستيميثات الصوديوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل زجاجة من كوليستين JPI ٢٠٠٠٠٠٠&nbsp;وحدة دولية مسحوق للحل للحقن/للتسريب/للاستنشاق على ٢٠٠٠٠٠٠ وحدة دولية كوليستيميثات الصوديوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا توجد مكونات أخرى.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كوليستين JPI ١٠٠٠٠٠٠ وحدة دولية مسحوق للحل للحقن/للتسريب/للاستنشاق هو كتلة صلبة بيضاء لها خصائص مظهر المستحضرات المعدة عن طريق التجفيف بالتبريد في زجاجات شفافة بحجم ١٠ مللتر من النوع رقم واحد مغطاة بسدادات مطاطية رمادية من الكلوروبيوتل وأغطية شفافة قابلة للفتح لأعلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كوليستين JPI ٢٠٠٠٠٠٠ وحدة دولية مسحوق للحل للحقن/للتسريب/للاستنشاق هو كتلة صلبة بيضاء لها خصائص مظهر المستحضرات المعدة عن طريق التجفيف بالتبريد في زجاجات شفافة بحجم ١٠ مللتر من النوع رقم واحد مغطاة بسدادات مطاطية رمادية من الكلوروبيوتل وأغطية خضراء قابلة للفتح لأعلى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حجم العبوة: ١٠ زجاجات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق</strong><strong> </strong><strong>و</strong><strong>محرر التشغيلة</strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة للمستحضر النهائي</strong></p><p dir="RTL">شركة الحكمة إيطاليا المساهمة العامة المحدودة<br />طريق سيرتوزا، 10<br />27100 بافيا، إيطاليا<br />هاتف: 1751844 (0382-39) +/ 1751801 (0382-39) +<br />فاكس: 422745 (0382-39) +</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul dir="rtl"><li>المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul dir="rtl"><li>دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p><ul dir="rtl"><li>الإمارات العربية المتحدة</li></ul><p dir="RTL">قسم اليقظة الدوائية والجهاز الطبي</p><p dir="RTL">صندوق بريد: 1853</p><p dir="RTL">هاتف: 80011111</p><p dir="RTL">البريد الإلكتروني: pv@mohap.gov.ae</p><p dir="RTL">إدارة الدواء</p><p dir="RTL">وزارة الصحة ووقاية المجتمع</p><p dir="RTL">دبي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 07/2023؛ رقم النسخة: Un3.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Colistin JPI 1,000,000 IU Powder for Solution for Injection/Infusion/Inhalation
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial of Colistin JPI 1,000,000 IU Powder for Solution for Injection/Infusion/Inhalation
contains 1,000,000 IU colistimethate sodium.

Excipient with known effect: Sodium. 

For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for Solution for Injection/Infusion/Inhalation

A white solid having characteristics appearance of products prepared by freeze drying.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Colistin JPI by intravenous administration is indicated in adults and children including neonates for the treatment of serious infections due to selected aerobic Gram-negative pathogens in patients with limited treatment options (see sections 4.2, 4.4, 4.8 and 5.1).</p><p>&nbsp;</p><p>Colistin JPI by inhalation is also indicated for the management of adult and paediatric chronic pulmonary infections due to&nbsp;<em>Pseudomonas aeruginosa</em>&nbsp;in patients with cystic fibrosis (see section 5.1).</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Systemic treatment</em></strong></p><p>The dose to be administered and the treatment duration should take into account the severity of the infection as well as the clinical response. Therapeutic guidelines should be adhered to.</p><p>&nbsp;</p><p>The dose is expressed in IU of colistimethate sodium (CMS). A conversion table from CMS in IU to mg of CMS as well as to mg of colistin base activity (CBA) is included at the end of this section.</p><p>&nbsp;</p><p><strong>Posology</strong></p><p>The following dose recommendations are made based on limited population-pharmacokinetic data in critically ill patients (see section 4.4):</p><p><em>&nbsp;</em></p><p><em>Adults and adolescents</em></p><p>Maintenance dose 9 million IU/day in 2-3 divided doses.</p><p>&nbsp;</p><p>In patients who are critically ill, a loading dose of 9 MIU should be administered.</p><p>&nbsp;</p><p>The most appropriate time interval to the first maintenance dose has not been established.</p><p>&nbsp;</p><p>Modelling suggests that loading and maintenance doses of up to 12 MIU may be required in patients with good renal function in some cases. Clinical experience with such doses is however extremely limited, and safety has not been established.</p><p>&nbsp;</p><p>The loading dose applies to patients with normal and impaired renal functions including those on renal replacement therapy.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Dose adjustments in renal impairment are necessary, but pharmacokinetic data available for patients with impaired renal function is very limited.</p><p>&nbsp;</p><p>The following dose adjustments are suggested as guidance.</p><p>&nbsp;</p><p>Dose reductions are recommended for patients with creatinine clearance &lt; 50 ml/min:</p><p>Twice daily dosing is recommended.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance</strong></p><p><strong>(ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>Daily dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>&lt; 50- 30</p></td><td style="vertical-align:top"><p>5.5- 7.5 MIU</p></td></tr><tr><td style="vertical-align:top"><p>&lt;30- 10</p></td><td style="vertical-align:top"><p>4.5- 5.5 MIU</p></td></tr><tr><td style="vertical-align:top"><p>&lt;10</p></td><td style="vertical-align:top"><p>3.5 MIU</p></td></tr></tbody></table><p>MIU = million IU</p><p>&nbsp;</p><p>Haemodialysis and continuous haemo(dia)filtration</p><p>Colistin appears to be dialyzable through conventional haemodialysis and continuous venovenous haemo(dia)filtration (CVVHF, CVVHDF). There are extremely limited data from population PK studies from very small numbers of patients on renal replacement therapy. Firm dose recommendations cannot be made. The following regimes could be considered.</p><p>&nbsp;</p><ul><li>Haemodialysis</li></ul><p>No-HD days: 2.25 MIU/day (2.2-2.3 MIU/day).</p><p>HD days: 3 MIU/day on haemodialysis days, to be given after the HD session.</p><p>Twice daily dosing is recommended.</p><p>&nbsp;</p><ul><li>CVVHF/ CVVHDF</li></ul><p>As in patients with normal renal function. Three times daily dosing is recommended.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>There are no data in patients with hepatic impairment. Caution is advised when administering colistimethate sodium in these patients.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustments in older patients with normal renal function are considered necessary.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The data supporting the dose regimen in paediatric patients are very limited. Renal maturity should be taken into consideration when selecting the dose. The dose should be based on lean body weight.</p><p>&nbsp;</p><ul><li>Children &le; 40kg</li></ul><p>75,000-150,000 IU/kg/day divided into 3 doses.</p><p>&nbsp;</p><p>For children with a body weight above 40 kg, use of the dosing recommendation for adults should be considered.</p><p>&nbsp;</p><p>The use of doses &gt;150,000 IU/kg/day has been reported in children with cystic fibrosis.</p><p>&nbsp;</p><p>There are no data regarding the use or magnitude of a loading dose in critically ill children.</p><p>&nbsp;</p><p>No dose recommendations have been established in children with impaired renal function.</p><p>&nbsp;</p><p><em>Intrathecal and intraventricular administration</em></p><p>Based on limited data, the following dose is recommended in adults:</p><p>Intraventricular route 125,000 IU/day</p><p>&nbsp;</p><p>Intrathecally administered doses should not exceed those recommended for intraventricular use.</p><p>&nbsp;</p><p>No specific dosing recommendation can be made in children for intrathecal and intraventricular routes of administration.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>Colistin JPI is administered intravenously as a slow infusion over 30 &ndash; 60 minutes.</p><p>&nbsp;</p><p>Patients with a totally implantable venous access device (TIVAD) in place may tolerate a bolus injection of up to 2 million units in 10 ml given over a minimum of 5 minutes (see section 6.6).</p><p>&nbsp;</p><p>Colistimethate sodium undergoes hydrolysis to the active substance colistin in aqueous solution. For dose preparation, particularly where combination of multiple vials is needed, reconstitution of the required dose must be performed using strict aseptic technique (see section 6.6).</p><p>&nbsp;</p><p><strong>Dose conversion table:</strong></p><p>In the EU, the dose of colistimethate sodium (CMS) must be prescribed and administered only as IU. The product label states the number of IU per vial.</p><p>&nbsp;</p><p>Confusion and medication errors have occurred because of the different expressions of dose in terms of potency. The dose is expressed in the US, and other parts of the world, as milligrams of colistin base activity (mg CBA).</p><p>&nbsp;</p><p>The following conversion table is prepared for information and the values must be considered nominal and approximate only.</p><p><strong>CMS conversion table</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Potency</p></td><td rowspan="2" style="vertical-align:top"><p>&asymp; mass of CMS (mg) *</p></td></tr><tr><td style="vertical-align:top"><p><strong>IU</strong></p></td><td style="vertical-align:top"><p><strong>&asymp; mg CBA</strong></p></td></tr><tr><td style="vertical-align:top"><p>12 500</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>150 000</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>12</p></td></tr><tr><td style="vertical-align:top"><p>1 000 000</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>80</p></td></tr><tr><td style="vertical-align:top"><p>4 500 000</p></td><td style="vertical-align:top"><p>150</p></td><td style="vertical-align:top"><p>360</p></td></tr><tr><td style="vertical-align:top"><p>9 000 000</p></td><td style="vertical-align:top"><p>300</p></td><td style="vertical-align:top"><p>720</p></td></tr></tbody></table><p>* Nominal potency of the drug substance = 12,500 IU/mg</p><p>&nbsp;</p><p><strong><em>Aerosol inhalation</em></strong></p><p>It is recommended that colistimethate sodium (CMS) should be administered under the supervision of physicians with appropriate experience in its use.</p><p>&nbsp;</p><p><strong>Posology</strong></p><p>The dosage can be adjusted depending on the severity of the condition and clinical response.</p><p>Recommended dose range:</p><p>&nbsp;</p><p><u>Administration via inhalation</u></p><p><em>Adults, adolescents and children &ge; 2 years</em></p><p>1-2 MIU two to three times per day (max 6 MIU/day)</p><p>&nbsp;</p><p><em>Children &lt; 2 years</em></p><p>0.5-1 MIU twice daily (max 2 MIU/ day)</p><p>Relevant clinical guidance on treatment regimens, including duration of treatment, periodicity and co-administration of other antibacterial agents should be adhered to.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Dose adjustment is not considered necessary</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Dose adjustment is not considered necessary, however caution is advised in patients with renal impairment (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Dose adjustment is not considered necessary</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>For inhalation use.</p><p>&nbsp;</p><p>Colistin JPI is intended for administration by nebulisation using a suitable nebulizer.</p><p>&nbsp;</p><p>Colistimethate sodium is very soluble in the reconstitution medium. The recommended technique for dissolving the medicinal product is the addition of 3 ml 0.9% w/w isotonic sodium chloride solution, to the vial containing Colistin JPI 1,000,000 IU by gentle shaking.</p><p>&nbsp;</p><p>Due to potential foaming, vigorous shaking should be avoided. The resulting solution for nebulisation should be clear and carefully transferred into the medication reservoir of the nebuliser.</p><p>&nbsp;</p><p>The solution is for single use only and any remaining solution should be discarded.</p><p>&nbsp;</p><p>The nebuliser must be kept according to the instructions of the corresponding nebuliser during operation.</p><p>&nbsp;</p><p>The patient should sit in an upright position and breathing normally during inhalation. Inhalation should be performed without any interruption to normal breathing.</p><p>&nbsp;</p><p>The nebuliser must be cleaned and disinfected after use as described in the &#39;instruction of use&#39; of the corresponding nebuliser.</p><p>&nbsp;</p><p>Colistimethate sodium undergoes hydrolysis to the active substance colistin in aqueous solution. For special precautions for disposal and handling of reconstituted solutions, see section 6.6.</p><p>&nbsp;</p><p>If other treatments are being taken, they should be taken in the order recommended by the physician.</p><p>&nbsp;</p><p><strong>Drug conversion</strong></p><p>See above for the Dose conversion table.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, colistin or to polymyxin B.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Consideration should be given to co-administering intravenous colistimethate sodium with another antibacterial agent whenever this is possible, taking into account the remaining susceptibilities of the pathogen(s) under treatment. As the development of resistance to intravenous colistin has been reported in particular when it is used as a monotherapy, co- administration with other antibacterial should also be considered in order to prevent the emergence of resistance.</p><p>&nbsp;</p><p>There are limited clinical data on the efficacy and safety of intravenous colistimethate sodium. The recommended doses in all subpopulations are equally based on limited data (clinical and pharmacokinetic/ pharmacodynamics data). In particular there are limited safety data for the use of high doses (&gt; 6MIU/day) and the use of a loading dose, and for special populations (patients with renal impairment and the paediatric population). Colistimethate sodium should only be used when other, more commonly prescribed antibiotics are not effective or not appropriate.</p><p>&nbsp;</p><p>Renal function monitoring should be performed at the start of treatment and regularly during treatment in all patients. The dose of colistimethate sodium should be adjusted according to creatinine clearance (see section 4.2). Patients who are hypovolaemic or those receiving other potentially nephrotoxic drugs are at increased risk of nephrotoxicity from colistin (see sections 4.5 and 4.8). Nephrotoxicity has been reported to be associated with cumulative dose and treatment duration in some studies. The benefit of prolonged treatment duration should be balanced against the potentially increased risk of renal toxicity.</p><p>&nbsp;</p><p>Few cases of pseudo-Bartter syndrome have been reported in children and adults with the intravenous use of colistimethate sodium. Monitoring of serum electrolytes should be started in suspected cases and appropriate management should be implemented, however, normalisation of electrolyte imbalance might not be achieved without discontinuation of colistimethate sodium.</p><p>Caution is advised when administering colistimethate sodium to infants &lt; 1 year of age as renal function is not fully mature in this age group. Further, the effect of immature renal and metabolic function on the conversion of colistimethate sodium to colistin is not known.</p><p>In case of an allergic reaction, treatment with colistimethate sodium must be discontinued and appropriate measures implemented.</p><p>&nbsp;</p><p>High serum concentrations of colistimethate sodium, which may be associated with overdosage or failure to reduce the dosage in patients with renal impairment, have been reported to lead to neurotoxic effects such as facial paraesthesia, muscle weakness<em>,&nbsp;</em>vertigo, slurred speech, vasomotor instability, visual disturbances, confusion, psychosis and apnoea. Monitoring should be performed for perioral paraesthesia and paraesthesia in the extremities, which are signs of overdose (see section 4.9).</p><p>&nbsp;</p><p>Colistimethate sodium is known to reduce the presynaptic release of acetyl-choline at the neuro-muscular junction and should be used in patients with myasthenia gravis with the greatest caution and only if clearly needed.</p><p>&nbsp;</p><p>Respiratory arrest has been reported following intramuscular administration of colistimethate sodium. Impaired renal function increases the possibility of apnoea and neuromuscular blockade following administration of colistimethate sodium.</p><p>&nbsp;</p><p>Colistimethate sodium should be used with extreme caution in patients with porphyria.</p><p>&nbsp;</p><p>Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all anti-bacterial agents and may occur with colistimethate sodium. They may range from mild to life-threatening in severity. It is important to consider this diagnosis in patients who develop diarrhoea during or after the use of colistimethate sodium (see section 4.8). Discontinuation of therapy and the administration of specific treatment for&nbsp;<em>Clostridium difficile&nbsp;</em>should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p>&nbsp;</p><p>Intravenous colistimethate sodium does not cross the blood brain barrier to a clinically relevant extent. The use of intrathecal or intraventricular administration of colistimethate sodium in the treatment of meningitis was not systematically investigated in clinical trials and is supported by case reports only. Data supporting the posology are very limited. The most commonly observed adverse effect of CMS administration was aseptic meningitis (see section 4.8).</p><p>&nbsp;</p><p>Bronchospasm may occur on inhalation of antibiotics. This may be prevented or treated with appropriate use of beta<sub>2</sub>-agonists. If troublesome, treatment should be withdrawn.</p><p>&nbsp;</p><p><strong>Colistin JPI contains sodium</strong></p><p>Colistin JPI contains sodium. Each vial of Colistin JPI 1,000,000 IU Powder for Solution for Injection/Infusion/Inhalation contains 0.2286 mmol (5.258 mg) sodium, equivalent to 0.2629% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant use of intravenous colistimethate sodium with other medications that are potentially nephrotoxic or neurotoxic should be undertaken with great caution.</p><p>Caution should be taken with concomitant use with other formulations of colistimethate sodium as there is little experience and there is a possibility of summative toxicity.</p><p>&nbsp;</p><p>No&nbsp;<em>in vivo&nbsp;</em>interaction studies have been performed. The mechanism of conversion of colistimethate sodium to the active substance, colistin, is not characterised. The mechanism of colistin clearance, including renal handling, is equally unknown. Colistimethate sodium or colistin did not induce the activity of any P 450 (CYP) enzyme tested (CYP1A2, 2B6, 2C8, 2C9, 2C19 and 3A4/5) in&nbsp;<em>in vitro&nbsp;</em>studies in human hepatocytes.</p><p>&nbsp;</p><p>The potential for drug-drug interactions should be borne in mind when colistimethate sodium is co-administered with drugs known to inhibit or induce drug metabolising enzymes or drugs known to be substrates for renal carrier mechanisms.</p><p>&nbsp;</p><p>Due to the effects of colistin on the release of acetylcholine, non-depolarising muscle relaxants should be used with caution in patients receiving colistimethate sodium as their effects could be prolonged (see section 4.4).</p><p>&nbsp;</p><p>Co-treatment with colistimethate sodium and macrolides such as azithromycin and clarithromycin, or fluoroquinolones such as norfloxacin and ciprofloxacin should be undertaken with caution in patients with myasthenia gravis (see section 4.4).</p><p>&nbsp;</p><p>Concomitant use of colistimethate sodium with other medicinal products of neurotoxic and/or nephrotoxic potential should be avoided. These include the aminoglycoside antibiotics such as gentamicin, amikacin, netilmicin and tobramycin. There may be an increased risk of nephrotoxicity if given concomitantly with cephalosporin antibiotics.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no adequate data from the use of colistimethate sodium in pregnant women. Single dose studies in human pregnancy show that colistimethate sodium crosses the placental barrier and there may be a risk of foetal toxicity if repeated doses are given to pregnant patients. Animal studies are insufficient with respect to the effect of colistimethate sodium on reproduction and development (see Section 5.3 &ndash; Preclinical safety data). Colistimethate sodium should be used in pregnancy only if the benefit to the mother outweighs the potential risk to the fetus.</p><p><strong>&nbsp;</strong></p><p>Colistimethate sodium is secreted in breast milk. Colistimethate sodium should be administered to breastfeeding women only when clearly needed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During parenteral treatment with colistimethate sodium neurotoxicity may occur with the possibility of dizziness, confusion or visual disturbance. Patients should be warned not to drive or operate machinery if these effects occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Systemic treatment</strong></p><p>The likelihood of adverse events may be related to the age, renal function and condition of the patient.</p><p>&nbsp;</p><p>In cystic fibrosis patients neurological events have been reported in up to 27% of patients. These are generally mild and resolve during or shortly after treatment.</p><p>&nbsp;</p><p>Neurotoxicity may be associated with overdose, failure to reduce the dose in patients with renal insufficiency and concomitant use of either neuromuscular blocking drugs or other drugs with similar neurological effects. Reducing the dose may alleviate symptoms. Effects may include apnoea, transient sensory disturbances (such as facial paraesthesia and vertigo) and, rarely, vasomotor instability, slurred speech, visual disturbances, confusion or psychosis.</p><p>&nbsp;</p><p>Adverse effects on renal function have been reported, usually following use of higher than recommended doses in patients with normal renal function, or failure to reduce the dosage in patients with renal impairment or during concomitant use of other nephrotoxic drugs. The effects are usually reversible on discontinuation of therapy.</p><p>&nbsp;</p><p>Pseudo-Bartter syndrome has been reported after intravenous administration of colistimethate sodium with unknown frequency (see section 4.4)</p><p>&nbsp;</p><p>In cystic fibrosis patients treated within the recommended dosage limits, nephrotoxicity appears to be rare (less than 1%). In seriously ill hospitalised non-CF patients, signs of nephrotoxicity have been reported in approximately 20% of patients.</p><p>&nbsp;</p><p>Hypersensitivity reactions including skin rash and drug fever have been reported. If these occur treatment should be withdrawn.</p><p>&nbsp;</p><p>Local irritation at the site of injection may occur.</p><p>&nbsp;</p><p><strong>Inhalation treatment</strong></p><p>Inhalation may induce coughing or bronchospasm.</p><p>&nbsp;</p><p>Sore throat or mouth has been reported and may be due to&nbsp;<em>Candida albicans</em>&nbsp;infection or hypersensitivity. Skin rash may also indicate hypersensitivity, if this occurs treatment should be withdrawn.</p><p>&nbsp;</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose can result in neuromuscular blockade that can lead to muscular weakness, apnoea and possible respiratory arrest. Overdose can also cause acute renal failure characterised by decreased urine output and increased serum concentrations of BUN and creatinine.</p><p>&nbsp;</p><p>There is no specific antidote, manage by supportive treatment. Measures to increase the rate of elimination of colistin e.g. mannitol diuresis, prolonged haemodialysis or peritoneal dialysis may be tried, but effectiveness is unknown.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antibacterials for systemic use, other antibacterials, polymyxins.</p><p>ATC Code: J01XB01.</p><p>&nbsp;</p><p><strong>Mechanism of action</strong></p><p>Colistin is a cyclic polypeptide antibacterial agent belonging to the polymyxin group. Polymyxins work by damaging the cell membrane and the resulting physiological effects are lethal to the bacterium. Polymyxins are selective for aerobic Gram-negative bacteria that have a hydrophobic outer membrane.</p><p>&nbsp;</p><p><strong>Resistance</strong></p><p>Resistant bacteria are characterised by modification of the phosphate groups of lipopolysaccharide, which become substituted with ethanolamine or aminoarabinose. Naturally resistant Gram-negative bacteria, such as&nbsp;<em>Proteus mirabilis&nbsp;</em>and&nbsp;<em>Burkholderia cepacia</em>, show complete substitution of their lipid phosphate by ethanolamine or aminoarabinose.</p><p>&nbsp;</p><p>Cross resistance between colistin (polymyxin E) and polymyxin B is expected. Since the mechanism of action of the polymyxins is different from that of other antibacterial agents, resistance to colistin and polymyxin by the above mechanism alone would not be expected to result in resistance to other drug classes.</p><p>&nbsp;</p><p><strong>PK/PD&nbsp;relationship</strong></p><p>Polymyxins have been reported to have a concentration-dependent bactericidal effect on susceptible bacteria. fAUC/ MIC is considered to be correlated with clinical efficacy.</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>EUCAST Breakpoints</strong></p></td><td style="vertical-align:top"><p>Susceptible (S)</p></td><td style="vertical-align:top"><p>Resistant (R)&nbsp;<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter</em></p></td><td style="vertical-align:top"><p>S&le;2</p></td><td style="vertical-align:top"><p>R&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td><td style="vertical-align:top"><p>S&le;2</p></td><td style="vertical-align:top"><p>R&gt;2 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas&nbsp;</em>spp</p></td><td style="vertical-align:top"><p>S&le;4</p></td><td style="vertical-align:top"><p>R&gt;4 mg/L</p></td></tr></tbody></table><p><sup>a&nbsp;</sup><em>Breakpoints apply to dosage of 2-3 MIU x 3. A loading dose (9 MIU) may be needed</em>.</p><p><strong>&nbsp;</strong></p><p><strong>Susceptibility</strong></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter baumannii</em></p><p><em>Haemophilus influenzae</em></p><p><em>Klebsiella spp</em></p><p><em>Pseudomonas aeruginosa</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Stenotrophomonas maltophilia</em></p><p><em>Achromobacter xylosoxidans (formerly Alcaligenes xylosoxidans)</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Burkholderia cepacia&nbsp;</em>and related species.</p><p><em>Proteus</em>&nbsp;species</p><p><em>Providencia</em>&nbsp;species</p><p><em>Serratia</em>&nbsp;species</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>The information on the pharmacokinetics of colistimethate sodium (CMS) and colistin is limited. There are indications that pharmacokinetics in critically ill patients differ from those in patients with less severe physiological derangement and from those in healthy volunteers. The following data are based on studies using HPLC to determine CMS/colistin plasma concentrations.</p><p>&nbsp;</p><p>After infusion of colistimethate sodium the inactive pro-drug is converted to the active colistin. Peak plasma concentrations of colistin have been shown to occur with a delay of up to 7 hours after administration of colistimethate sodium in critically ill patients.</p><p>&nbsp;</p><p>Absorption from the gastrointestinal tract does not occur to any appreciable extent in the normal individual.</p><p>&nbsp;</p><p>When given by nebulisation, variable absorption has been reported that may depend on the aerosol particle size, nebuliser system and lung status. Studies in healthy volunteers and patients with various infections have reported serum levels from nil to potentially therapeutic concentrations of 4 mg/l or more. Therefore, the possibility of systemic absorption should always be borne in mind when treating patients by inhalation.</p><p>&nbsp;</p><p><strong>Distribution</strong></p><p>The volume of distribution of colistin in healthy subjects is low and corresponds approximately to extracellular fluid (ECF). The volume of distribution is relevantly enlarged in critically ill subjects. Protein binding is moderate and decreases at higher concentrations. In the absence of meningeal inflammation, penetration into the cerebrospinal fluid (CSF) is minimal, but increases in the presence of meningeal inflammation.</p><p>&nbsp;</p><p>Both CMS and colistin display linear PK in the clinically relevant dose range.</p><p>&nbsp;</p><p><strong>Elimination</strong></p><p>It is estimated that approximately 30% of colistimethate sodium is converted to colistin in healthy subjects, its clearance is dependent on creatinine clearance and as renal function decreases, a greater portion of CMS is converted to colistin. In patients with very poor renal function (creatinine clearance &lt;30 ml/min), the extent of conversion could be as high as 60 to 70%. CMS is eliminated predominantly by the kidneys via glomerular filtration. In healthy subjects, 60% to 70% of CMS is excreted unchanged in the urine within 24 hours.</p><p>&nbsp;</p><p>The elimination of the active colistin is incompletely characterised. Colistin undergoes extensive renal tubular reabsorption and may either be cleared non-renally or undergo renal metabolism with the potential for renal accumulation. Colistin clearance is decreased in renal impairment, possibly due to increased conversion of CMS.</p><p>&nbsp;</p><p>Half-life of colistin in healthy subjects and those with cystic fibrosis is reported to be around 3h and 4h, respectively, with a total clearance of around 3L/h. In critically ill patients, half-life has been reported to be prolonged to around 9-18h.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Data on potential genotoxicity are limited and carcinogenicity data for colistimethate sodium are lacking. Colistimethate sodium has been shown to induce chromosomal aberrations in human lymphocytes, <em>in vitro</em>. This effect may be related to a reduction in mitotic index, which was also observed.</p><p>&nbsp;</p><p>Reproductive toxicity studies in rats and mice do not indicate teratogenic properties. However, colistimethate sodium given intramuscularly during organogenesis to rabbits at 4.15 and 9.3 mg/kg resulted in talipes varus in 2.6 and 2.9% of fetuses respectively. These doses are 0.5 and 1.2 times the maximum daily human dose. In addition, increased resorption occurred at 9.3 mg/kg.</p><p>&nbsp;</p><p>There are no other preclinical safety data of relevance to the prescriber which are additional to safety data derived from patient exposure and already included in other sections of the SPC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mixed infusions, injections and nebuliser solutions involving colistimethate sodium should be avoided.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Before opening: 24 months.

Reconstituted solutions:
Hydrolysis of colistimethate is significantly increased when reconstituted and diluted below its critical micelle concentration of about 80,000 IU per ml.

Solutions below this concentration should be used immediately.
	
For solutions for bolus injection or nebulisation, the chemical and physical in-use stability of reconstituted solution for Colistin JPI 1,000,000 IU Powder for Solution for Injection/Infusion/Inhalation in the original vial, with a concentration ≥ 80,000 IU/ml, has been demonstrated for 2 hours at room temperature or for 6 hours in a refrigerator (2-8ᵒC).
	
From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbial contamination, the product should be used immediately.

If not used immediately, in-use storage times and conditions are the responsibility of user.

Solutions for infusion, which have been diluted beyond the original vial volume and/or with a concentration < 80,000 IU/ml should be used immediately.

For solutions for intrathecal and intraventricular administration, the reconstituted product should be used immediately.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>For solutions for bolus injection or nebulisation, the chemical and physical in-use stability of reconstituted solution in the original vial, with a concentration &ge; 80,000 IU/ml, has been demonstrated for 2 hours at room temperature or for 6 hours in a refrigerator (2-8ᵒC).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 ml type I clear glass vials with grey chlorobutyl rubber stoppers with transparent flip-off caps.</p><p><strong>&nbsp;</strong></p><p>Pack size: 10 Vials.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>For bolus injection: </strong></p><p>Reconstitute the contents of the vial with not more than 10 ml water for injection or 0.9% sodium chloride.</p><p>&nbsp;</p><p><strong>For infusion:</strong></p><p>The contents of the reconstituted vial of Colistin JPI 1,000,000 IU Powder for Solution for Injection/Infusion/Inhalation with 5 ml water for injection may be diluted, usually with 50 ml 0.9% sodium chloride, dextrose, fructose or ringer.</p><p>&nbsp;</p><p><strong>For inhalation by nebuliser:</strong></p><p>Reconstitute the contents of the vial with either water for injections or with 9 mg/ml (0.9% solution) sodium chloride.</p><p>&nbsp;</p><p>Colistimethate sodium is very soluble in the reconstitution medium. The recommended technique for dissolving the medicinal product is the addition of 3 ml isotonic sodium chloride solution for the vial containing Colistin JPI by gentle shaking.</p><p>&nbsp;</p><p>The output from the nebuliser may be vented to the open air or a filter may be fitted. Nebulisation should take place in a well ventilated room.</p><p>&nbsp;</p><p>Solutions are for single use only and any remaining solution should be discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12 July 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>